Crossmark

CMAB009 plus irinotecan versus irinotecan‐only as second‐line treatment after fluoropyrimidine and oxaliplatin failure in <i>KRAS</i> wild‐type metastatic colorectal cancer patients: promising findings from a prospective, open‐label, randomized, phase III trial

Crossref DOI link: https://doi.org/10.1186/s40880-019-0374-8

Published Online: 2019-05-24

Published Print: 2019-12

Update policy: https://doi.org/10.1002/crossmark_policy

Authors

Shi, Yuankai http://orcid.org/0000-0002-8450-7583
Li, Jin

Xu, Jianming

Sun, Yan

Wang, Liwei

Cheng, Ying

Liu, Wei

Sun, Guoping

Chen, Yigui

Bai, Li

Zhang, Yiping

He, Xiaohui

Luo, Yi

Wang, Zhehai

Liu, Yunpeng

Yao, Qiang

Li, Yuhong

Qin, Shukui

Hu, Xiaohua

Bi, Feng

Zheng, Rongsheng

Ouyang, Xuenong
Funding

Funding for this research was provided by:

Shanghai Zhangjiang Biotechnology Co., Ltd.

Chinese National Major Project (2012ZX09101103, 2013ZX09101002-001-001, 2008ZX09312)
License Information

Version of Record valid from 2019-05-24
More Information

Publication History

Received: 2018-07-24

Accepted: 2019-05-10

Published: 2019-05-24

Document is current

Any future updates will be listed below